SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Job Trends
Bonus Episode: Q1 2025 Job Market Update
In this bonus episode, BioSpace’s vice president of marketing ⁠Chantal Dresner⁠ and careers editor ⁠Angela Gabriel⁠ take a look at Q1 job market performance, layoffs and administration decisions impacting the workforce.
April 15, 2025
 · 
1 min read
 · 
Angela Gabriel
Graphic art composition. hand points at tax pie chart near professional, showing process of tax allocation, budgeting, and financial oversight. Concept of business, budgeting, management. Ad
Tariffs
J&J CEO Duato Urges Tax Fix, Not Tariffs To Drive US Pharma Manufacturing
In the company’s first-quarter earnings call Tuesday, J&J CEO Joaquin Duato said there’s a better way to encourage drug manufacturing in the U.S. than President Donald Trump’s threatened pharma tariffs.
April 15, 2025
 · 
3 min read
 · 
Annalee Armstrong
Feb 2, 2020 South San Francisco / CA / USA - Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Collaboration
Merck Eyes Oral Peptide Delivery With Cyprumed Deal Worth up to $493M
Merck has not disclosed which of its peptide therapies it plans to develop oral formulations for.
April 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's office in Madrid, Spain
Earnings
J&J Beats Q1 Analyst Estimates Thanks To Tremfya, Carvykti, While Stelara Fades
J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the remaining $8 billion.
April 15, 2025
 · 
2 min read
 · 
Annalee Armstrong
Modern process Heart inner organs disease treatment design concept with Tiny People Character Vector Illustration
Cardiovascular disease
BMS’ Camzyos Fails To Show New Cardiomyopathy Benefit in Phase III
According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion label expansion opportunity for Camzyos.
April 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Collaboration
Boehringer Ingelheim Boosts I&I Portfolio With $357M in Biobucks for Cue
At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address autoimmune and inflammatory conditions.
April 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Symbol of money dollar from colored pills and capsules on green background. Expensive medicine and medical insurance
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Scientists working with DNA. Doctors doing laboratory research. Medicine and technology. Genetic testing DNA testing genetic diagnosis concept. Vector, illustration, esp.
Gene editing
Verve’s Base Editor ‘Numerically Beats’ Other Cholesterol-Lowering Drugs
In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.
April 14, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Businessman pulling rope trying to lift up falling graph.
Weight Loss
Viking Rises as Pfizer’s Oral Obesity Med Falters
Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron. But the biotech has a long way to go to recover after six straight months of decline.
April 14, 2025
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS